Literature DB >> 16520998

Prescription of rh-APC differs substantially among western European countries.

Marcus J Schultz, Marcel Levi.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16520998     DOI： 10.1007/s00134-006-0075-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  6 in total

1.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Authors:  Jean-Louis Vincent; Gordon R Bernard; Richard Beale; Christopher Doig; Christian Putensen; Jean-Francois Dhainaut; Antonio Artigas; Roberto Fumagalli; William Macias; Theressa Wright; Kar Wong; David P Sundin; Mary Ann Turlo; Jonathan Janes
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

3.  Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.

Authors:  A Davies; S Ridley; J Hutton; C Chinn; B Barber; D C Angus
Journal:  Anaesthesia       Date:  2005-02       Impact factor: 6.955

4.  An economic evaluation of activated protein C treatment for severe sepsis.

Authors:  Braden J Manns; Helen Lee; Christopher James Doig; David Johnson; Cam Donaldson
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

Review 5.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; Mitchell M Levy
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

6.  Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Authors:  Gordon R Bernard; Benjamin D Margolis; Harvey M Shanies; E Wesley Ely; Arthur P Wheeler; Howard Levy; Kar Wong; Theressa J Wright
Journal:  Chest       Date:  2004-06       Impact factor: 9.410
  6 in total
  4 in total

1.  Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study.

Authors:  Laurent Muller; Samir Jaber; Alice Raillard; Jean Yves Lefrant
Journal:  Intensive Care Med       Date:  2008-01-23       Impact factor: 17.440

2.  Drotrecogin alfa (activated): down and not out, but not really in either.

Authors:  Jan O Friedrich; Neill K J Adhikari; Maureen O Meade
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

3.  Intensive insulin therapy in intensive care: an example of the struggle to implement evidence-based medicine.

Authors:  Marcus J Schultz; Annick A N M Royakkers; Marcel Levi; Hazra S Moeniralam; Peter E Spronk
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

4.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.